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Recombinant adenovirus IL-24-Bax promotes apoptosis of
hepatocellular carcinoma cells in vitro and in vivo
JL i
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Gene therapy promises to become an alternative choice for the treatment of hepatic cancer. In many cancers, the delivery of
chimeric proteins by adenovirus vector has been reported to induce apoptosis. This study was performed to evaluate whether the
recombinant adenovirus interleukin (IL)-24-Bax can induce apoptosis in hepatocellular carcinoma cells in vitro and in vivo. Several
recombinant adenoviruses were constructed, and the expression of their encoded proteins was measured. The effects of the
recombinant adenovirus on hepatocellular carcinoma cells and the normal hepatocyte cell line were investigated through cell
viability and apoptosis assays after the cells were treated with Ad.Luc, Ad.IL-24, Ad.Bax or Ad.IL-24-Bax. The mechanism involved
was also explored. A tumor-bearing mouse model was used to evaluate the effects of the adenovirus on tumor volume and cell
apoptosis in vivo. Ad.IL-24-Bax selectively suppressed growth of hepatocellular carcinoma cells and induced apoptosis, but it had
little influence on the normal hepatocytes. The mechanism of this response may include the effect of the 10HRE/VEGF385 promoter
and the synergistic effect of IL-24 and Bax. Ad.IL-24-Bax also suppressed tumor growth in nude mice and induced apoptosis.
Ad.IL-24-Bax may be a useful tool for gene therapy of hepatic cancer.
Cancer Gene Therapy (2010) 17, 771–779; doi:10.1038/cgt.2010.34; published online 2 July 2010
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Introduction
Current therapies for malignancies do not have a
satisfactory patient survival rate, so novel approaches to
treat these diseases have been extensively studied. Gene
therapy represents an alternative form of treatment for
cancer and may be used to treat malignancies. One
strategy is to combine molecular targeting with a toxic
molecule.
1 Some chimeric toxins have already undergone
clinical trials. However, several disadvantages limit the
clinical application of chimeric toxins.
2–4 One disadvan-
tage of targeted chimeric toxins is that the bacterial toxins
are recognized as foreign by the immune system of the
recipients; another is that the nonspecific toxicity of the
chimeric toxins limits its dosage and persistent applica-
tion. To overcome these problems, a new generation of
chimeric proteins have been developed using human
apoptosis-inducing factors. Interleukin (IL)-2-Bax is the
first prototype of this class. IL-2-Bax specifically targets
IL-2R-expressing cells and induces cell specific,
dose-dependent apoptosis.
5,6
Bax is a proapoptotic member of the Bcl-2 protein
family, and has been reported to induce apoptosis in
cancer cells after transfection; it can also inhibit growth of
many tumor types. Bax can increase the permeability of
the mitochondrial outer membrane, leading to the release
of apoptosis molecules such as cytochrome C.
7–9 p53 has
been shown to initiate the mitochondrial apoptosis by
modulating the expression of Bcl-2 family members,
including Bax.
10 Mutations in p53 frequently occur in
tumors, so a chimeric toxin harboring Bax may be able to
activate the mitochondrial apoptosis pathway regardless
of p53 status. In other words, Bax could successfully
replace bacterial or phytotoxins. For this study, Bax fused
with IL-2 or IL-3 was confirmed to accumulate to the
target cell and induce cell death.
IL-24, previously named melanoma differentiation
associated gene-7 (mda-7), was originally identified by
subtraction hybridization as a novel molecule of unknown
function, and its expression is elevated in terminally
differentiated human melanoma cells.
11 IL-24 was initially
shown to possess cellular growth arresting properties.
12,13
Several independent studies have shown that a majority of
human cancer derived cell lines, including melanoma,
prostate, breast, cervical, lung, fibrosarcoma, pancreatic,
colorectal and glioblastoma underwent apoptosis when
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14–16 Most tumor cell surfaces
express IL-24 receptor, and purified mda-7/IL-24 can
specifically induce apoptosis of tumor cell in a receptor-
dependent way.
17–19 Thus, IL-24 not only can specifically
induce tumor cell apoptosis, but also can act as a
targeting molecule like IL-2 or IL-3, specifically targeting
other molecules into a tumor cell.
Reports have shown that p53 mutations and decreased
Bax activation are common in hepatocellular carcinoma
cells.
20,21 mda-7/IL-24 has been reported to induce
apoptosis in hepatocellular carcinoma cells.
22,23 In this
study, IL-24 and Bax were fused and then introduced into
adenovirus (Ad.IL-24-Bax). The activity of the chimeric
protein IL-24-Bax was examined both in vitro and in vivo,
especially its effect on apoptosis in hepatocellular
carcinoma cells and in tumor-bearing nude mice model.
Furthermore, the possible mechanism was also investi-
gated and discussed.
Materials and methods
Cell lines and culture conditions
Human embryonic kidney cells (HEK-293), human
hepatocellular carcinoma cell lines (HepG2, Hep3B,
PLC/PRF/5) and human hepatocyte line L02 were
originally obtained from the American Type Tissue
Culture Collection (Rockville, MD). HepG2 and L02
cells were incubated in Dulbecco’s Modified Eagle Media
supplemented with 10% fetal bovine serum, 100Uml
 1
penicillin and 100mgml
 1 streptomycin at 371Ci na n
atmosphere of 5% CO2 and 100% humidity. Hep3B and
PLC/PRF/5 cells were incubated in RPMI 1640 (Invitro-
gen, Karlsruhe, Germany) supplemented with 10% fetal
bovine serum (PAA Laboratories GmbH, Pasching,
Austria), 100Uml
 1 penicillin and 100mgml
 1 streptomycin
at 371C in an atmosphere of 5% CO2 and 100% humidity.
The cells were passaged twice per week, and 0.25% trypsin
with 1mM EDTA was used to isolate the cells.
Construction of recombinant adenovirus
The recombinant adenovirus was commercially con-
structed by Vector Gene Technology Company Limited
(Beinjing, China). For recombinant adenovirus IL-24-Bax
(Ad.IL-24-Bax), 515bp 10 HRE/VEGF385 (HRE:
50-GTGACTACGTGCTGCCTAG-30) was introduced into
the pGL3-SV40 promoter vector using SacI/XhoI restric-
tion sites. A segment from human IgG1 (gag gct tct ggt
ggt ggt cct gaa) was used to link the cDNA of Baxa and
the cDNA of IL-24. A 6 His (ATGATGATGATG
ATGATG) tag was introduced before the stop codon.
Then, the recombinant segment of IL-24-Bax was
introduced into the plasmid with the 10 HRE/
VEGF385 promoter using the Xbal/HindIII restriction
sites. After restriction digestion with KpnI/SalI, the 2.3kb
recombinant segment was introduced into the AdEasy
Adenoviral Vector System (Quantum Biotech, Montreal,
Canada). Subsequently, the vector was enclosed, ampli-
fied and purified in HEK-293 cells. Other recombinant
adenoviruses (Ad.IL-24, Ad.Bax and Ad.Luc) were
similarly constructed.
To assess the optimal multiplicity of infection (MOI)
for maximal transgene expression, Hep3B cells were
infected with Ad.IL-24-Bax at various MOIs and
examined by fluorescence microscopy. Twenty-four hours
before transfection with recombinant adenovirus vector at
different MOIs, cells were transferred to a six-well plate at
a density of 2 10
5 cells per well. The medium was
changed 2h after the transfection was completed, then the
cells were cultured for another 72h before observation by
fluorescent microscopy.
Western blotting analysis
After transfection, the expression of recombinant IL-24-
Bax in transfected cells was detected using western
blotting analysis. The analysis was performed 48h after
the transfection. Cellular proteins were collected and the
concentration was determined using the Bio-Rad method
(Bio-Rad, San Francisco, CA). The protein was analyzed
by SDS-PAGE electrophoresis and electrotransferred to a
nitrocellulose membrane. Then the filters were incubated
in 5% nonfat milk solution at room temperature for 2h to
block nonspecific antibody binding. Subsequently, the
filters were incubated in primary antibody solution for
2h. The respective primary antibodies were as follows:
rabbit anti-human IL-24 (Santa Cruz Biotechnology,
Santa Cruz, CA), rabbit anti-human p53 (Santa Cruz
Biotechnology), rabbit anti-human BiP/GRP78 (Biovi-
sion Research Products, Mountain View, CA), rabbit
anti-human Caspase-12 (Biovision Research Products),
rabbit anti-human Caspase-3 (Cell Signaling, Beverly,
MA), rabbit anti-human b-actin (Cell Signaling) and
mouse anti-human Bax (Santa Cruz Biotechnology). The
filters were then incubated in peroxidase-labeled goat
anti-rabbit IgG or goat anti-mouse IgG (Santa Cruz
Biotechnology). The filters were developed by ECL
(Pierce, Rockford, IL), and images were generated after
exposure to X-ray film. The images were analyzed by
Quantity One. The relative gray scale value was the ratio
of the gray scale of the test protein band vs the gray scale
of the b-actin band. The relative gray scale value
represented the relative protein expression.
Western blotting analysis was also performed to
investigate the recombinant protein expression under
normal condition and anoxia condition. L02, Hep3B,
HepG2 and PLC/PRF/5 cells were cultured in six-well
plates at density of 2 10
5 per well. After the cells
adhered, the recombinant adenovirus (MOI¼10) was
added to the cells and incubated for 48h. Then cells were
randomly divided into two groups. One group was
cultured in an atmosphere of 95% air and 5% CO2,
whereas another group was cultured in an atmosphere of
95% N2 and 5% CO2. Before protein collection, cells were
cultured in serum-free medium for 4, 8 and 16h,
respectively. The expression of IL-24-Bax was detected
by western blotting analysis as described earlier.
Cell viability assay
The effects of recombinant adenovirus on cell growth
were determined using a methyl thiazolyl tetrazolium cell
viability assay as described earlier. Cells in logarithmic
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density of 10
5 cells  100ml per well. Then the recombi-
nant adenovirus at different MOI (0.01–100) diluted in
serum-free medium was added to the wells. Cells were
cultured for another 3 days. Then, the culture medium
was replaced with 100ml serum-free medium with 20ml
methyl thiazolyl tetrazolium (5mgml
 1)a t3 71C for 5h.
Finally, the medium was discarded and 150ml dimethyl
sulfoxide solution was added to each well to lyse cells.
Absorbance was measured at A570nm. Each experiment
was repeated three times. Cell viability was calculated as
the ratio of the absorbance of the test group vs the
absorbance of the control group. A cell growth curve was
constructed based on the cell viability data.
Apoptosis assay by flow cytometry
Before induction of cell apoptosis, the cultured cells were
treated for 30min with the endoplasmic reticulum (ER)
inhibitor calpastatin I (ALLN, N-Ac-L-L-norleucinal,
25mM, Calbiochem, Darmstadat, Germany). Then the
cultured cells were incubated with adenovirus (MOI¼10)
for 48h. Later, cells were isolated using trypsin and
collected by centrifugation. A total of 2 10
6 cells were
analyzed by flow cytometry. Before analysis, cells were
fixed in 75% ethanol overnight and stained with Annexin
V-fluorescein isothiocyanate/proliferation index for 30min.
Cell cycle analysis was performed using a FACSaria flow
cytometer (Becton Dickinson, Franklin Lakes, NJ). All
data were analyzed using Modifit3.0 software.
Western blots were performed to investigate the mechan-
ism involved in the induction of apoptosis. The expression
of mitochondrial pathway related proteins (caspase-3, Bax)
and ER-stress pathway related proteins (Bip/GRP78,
caspase-12) were measured after Hep3B cells were treated
with Ad.Luc, Ad.Bax, Ad.IL-24 or Ad.IL-24-Bax
(MOI¼10) for 48h. On the other hand, after the ER-
stress pathway was blocked by ALLN, the expression of
related proteins was also measured after Hep3B cells were
similarly treated by recombinant adenovirus.
In vivo study using tumor-bearing nude mouse models
All procedures were performed in accordance with the
guidelines and approval of the local Institutional Animal
Experimentation Ethics Committee. BALB/c-nu/nu mice
were purchased from Shanghai Laboratory Animal
Research Center of the Chinese Academy of Sciences
and were bred in the specific pathogen-free animal
laboratory in the Second Military Medical University.
All mice were maintained in specific pathogen-free
facilities and fed with irradiated food. BALB/c-nu/nu
mice were age matched (4–5 weeks of age) at the
beginning of each experiment. Hep3B cells were injected
subcutaneously into the back of athymic mice (5 10
6
cells/each). Mice were observed and weighed everyday.
When the tumor diameter reached 4–5mm, 40 mice
bearing tumors were randomly divided into four groups:
Ad.IL-24-Bax, Ad.IL-24, Ad.Bax and Ad.Luc. The
adenovirus was intratumorally injected at a single site at
the dose of 2 10
8PFU per 100ml once every 4 days for
three times. Three weeks after the first injection, mice
were killed by dislocation of cervical vertebra. Tumors
were weighed and tumor volume was measured using a
vernier caliper. The tumor volume was calculated using
the following formula: tumor volume ¼0.5 a b
2,
where a is the longer diameter and b is the shorter
diameter. Tumors were fixed in 10% paraformaldehyde
solution before further analysis.
Immunochemistry and apoptosis assay
Tumor tissue was first sliced, fixed and dehydrated and then
it underwent immunochemistry using the EliVision plus assay
kit (Zymed Biotechnology, Zymed, CA) following the
manufacture’s instructions. Rabbit anti-human Ki-67 mono-
clonal antibody (Santa Cruz Biotechnology) was applied in
the assay. The known positive slide was used as the positive
control, and phosphate buffered saline was used as the
negative control. Five areas ( 400) were randomly observed.
For each area, 200 cells were counted and the positive cell
number was recorded. The count was repeated three times
and the percentage of positive cells was calculated.
Apoptosis assays were performed using the transferase-
mediated dUTP nick-end-labeling method. The tumor
cells were labeled using the Fluorescein-FragEL DNA
Fragmentation Detection Kit following the manufac-
turer’s protocol (Oncogene Research Products, Boston,
MA) and then observed under a fluorescent microscope.
Areas ( 400) where positive cells were evenly distributed
were observed. Three hundred cells were counted and the
number of positive cells was recorded. The count was
repeated three times and the percentage of positive cells
was calculated.
Statistical analysis
All statistical analysis was performed using the SPSS10.0
software. The statistical significance was determined by a
t-test of independent samples and analysis of variance.
P-values for significance were set at 0.05.
Results
Construction of recombinant adenovirus
As Figure 1a shows, the recombinant adenovirus IL-24-
Bax was constructed as well as Ad.IL-24, Ad.Bax and
Ad.Luc. When Hep3B cells were transfected with Ad.IL-
24-Bax, the transfection efficiency was related to the MOI
of the recombinant adenovirus. As the MOI increased, the
efficiency of transfection also increased. When MOI was
higher than 25, the efficiency of transfection was as high
as 90%. Considering the cytotoxicity of the virus, an MOI
of 10 for the virus was used in transfection experiments in
this study.
The results of the western blotting analysis confirmed
the expression of the chimeric protein (Figure 1b).
Antibodies to IL-24 and Bax, respectively, detected the
protein segment of IL-24 and Bax.
Anoxia induces IL-24-Bax expression in hepatocellular
carcinoma cells but not in normal hepatocytes
Figure 2 shows the expression of IL-24-Bax in Hep3B,
HepG2, L02 and PLC/PRF/5 cells after cells were
IL-24-Bax gene therapy for cancer
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expression was higher when cells were cultured in anoxic
conditions than in cells cultured under normal conditions.
The expression increased over time in anoxic conditions.
After the cells were cultured under anoxic conditions for
16h, the expression of IL-24-Bax in Hep3B, HepG2 and
PLC/PRF cells was 1.71, 4.16 and 1.5 times that of cells
cultured in normal conditions. However, the expression of
IL-24-Bax in L02 cells remained the same regardless of
the culture conditions. The results indicated that insertion
of the HRE promoter repeats enhanced the specific
expression of Ad.IL-24-Bax under anoxic conditions in
hepatocytes.
Ad.IL-24-Bax inhibited hepatocellular carcinoma cell
growth and prompted apoptosis in vitro
Figure 3a illustrated the cell viability of Hep3B, PLC/
PRF/5, HepG2 and L02 cells after transfection with the
recombinant adenovirus at different MOIs. When trans-
fected and cultured with Ad.IL-24 and Ad.IL-24-Bax at
high MOI, the growth of hepatocellular carcinoma cells
was significantly inhibited. When the MOI was 410, the
survival rate of hepatocellular carcinoma cells was
significantly lower when transfected and cultured with
Ad.IL-24-Bax than with Ad.IL-24 (Po0.05). Meanwhile,
the growth curve of normal hepatocyte L02 was not
significantly changed (P40.05) when transfected and
cultured with Ad.Bax, Ad.IL-24 or Ad.IL-24-Bax. When
transfected and cultured with Ad.Luc, the growth curves
of normal hepatocytes and hepatocellular carcinoma cells
were similar.
The results of the flow cytometry assay (Figure 3b)
indicated that Ad.IL-24-Bax promoted apoptosis of
hepatocellular carcinoma cells but had no obvious
cytotoxicity to normal hepatocytes. The apoptosis rate
of three hepatocellular carcinoma cell lines was signifi-
cantly higher when transfected with Ad.IL-24-Bax than
those transfected with Ad.IL-24 or Ad.Bax (Po0.05).
The apoptosis rate of the normal hepatocyte line L02 was
not significantly different when transfected with Ad.Luc,
Ad.IL-24, Ad.Bax or Ad.IL-24-Bax (P40.05). The results
indicated that Ad.IL-24-Bax robustly inhibited hepato-
cellular carcinoma cell growth and induced apoptosis
while having no obvious toxic side effects.
The possible mechanism involved in the cell apoptosis
To determine whether apoptosis was induced by the ER-
stress pathway, the expression of related proteins in p53-
absent Hep3B cells was examined. Figure 4a showed that
after transfection with Ad.IL-24-Bax, BiP/GRP78 was
highly expressed, caspase-12 was activated and endogen-
ous Bax was highly expressed in Hep3B cells. Further-
more, after transfection with Ad.IL-24-Bax and treatment
with the ALLN, an inhibitor of the ER-stress pathway,
the activation of caspase-12 was significantly inhibited,
L02
I
L
-
2
4
/
β
-
a
c
t
i
n
 
g
r
a
y
 
s
c
a
l
e
 
r
a
t
i
o
0.4
0.3
0.2
0.1
0
normoxic anoxic 4 h anoxic 8 h anoxic 16 h
1234 1234
IL-24
β-actin
1234 234 1
Hep3B HepG2 PLC/PRF/5
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Figure 3 Ad.IL-24-Bax suppressed the proliferation of hepatocellular carcinoma cells and induced apoptosis in hepatocellular carcinoma
in vitro.( a) Cell viability after Ad.IL-24-Bax treatment by methyl thiazolyl tetrazolium assays. Normal hepatocyte (L02) and hepatocellular
carcinoma cells (HepG2, Hep3B, PLC/PRF/5) were treated with Ad.Luc (B), Ad.Bax ( ), Ad.IL-24 (m) or Ad.IL-24-Bax (’) at different
multiplicities of infection (MOI). Three days after infection, the cell survival rate was checked. Ad.IL-24-Bax inhibited hepatocellular carcinoma cell
growth, while having little influence on the growth of normal liver cells. (b) Percentage of apoptotic cells after Ad.IL-24-Bax treatment using the
Annexin V-fluorescein isothiocyanate/proliferation index staining method. Normal hepatocytes (L02) and hepatocellular carcinoma cells (HepG2,
Hep3B, PLC/PRF/5) were treated with Ad.Luc, Ad.Bax, Ad.IL-24 or Ad.IL-24-Bax (MOI¼10) for 72h. Cells were harvested for Annexin V-
fluorescein isothiocyanate/proliferation index staining analysis.
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caspase-3 were not significantly influenced (Figure 4b).
Ad.IL-24-Bax suppressed tumor growth and induced
cell apoptosis in tumor-bearing nude mice
Figure 5 shows that the tumor volume in the Ad.IL-24-
Bax group was significantly smaller compared with that
of the Ad.Luc, Ad.Bax or Ad.IL-24 group (Po0.05).
More importantly, compared with the other groups, the
expression of Ki-67 was significantly lower in the Ad.IL-
24-Bax group, as evidenced by immunohistochemistry
and assessment of the proliferation index (Figure 6).
As measured by transferase-mediated dUTP nick-end-
labeling assay (Figure 6), the number of apoptotic Hep3B
cells was significantly more in the Ad.IL-24-Bax group
than in other groups. These results indicate that Ad.IL-
24-Bax inhibited the growth and proliferation of Hep3B
tumors and induced tumor apoptosis in vivo.
Discussion
Hepatocellular carcinoma is a major malignant solid
tumor worldwide, and its incidence keeps increasing in the
United States as well as in other parts of the world. The
current therapies include traditional surgical procedures
and newly emerged minimally invasive therapy. However,
the post-operation recurrence rate and the metastasis rate
remain high. Hepatocellular carcinoma is insensitive to
chemotherapy and radiotherapy and can easily develop
tolerance. Generally, most patients with hepatocellular
carcinoma do not respond well to therapy. Thus, new
therapies, such as gene therapy and molecular targeted
therapy should be studied for the treatment of hepato-
cellular carcinoma.
24
Recent studies including our study have shown that
mda-7/IL-24 could selectively induce apoptosis of hepa-
tocellular carcinoma cells,
22,23 and its effect was related to
the ER-stress pathway.
23 In this study, IL-24 and Bax,
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GRP78, caspase-12, caspase-3 and Bax proteins were detected by
western blot analysis. b-Actin was used as the internal standard.
t
u
m
o
r
 
v
o
l
u
m
e
 
(
m
m
3
)
700
600
500
400
300
200
100
0
Ad.Luc Ad.Bax Ad.IL-24 Ad.IL-24-Bax
T
u
m
o
r
 
w
e
i
g
h
t
 
(
g
)
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
Ad.Luc Ad.Bax Ad.IL-24 Ad.IL-24-Bax
days
*
*
#
*
0 4 8 12 16 20 24
Figure 5 Ad.IL-24-Bax suppressed liver tumor growth in tumor-
bearing nude mice model. (a) The tumor-bearing BALB/c mice
(n¼10) were subcutaneously injected with Ad.Luc (}), Ad.Bax ( ),
Ad.IL-24 (m) or Ad.IL-24-Bax (’)( 2  10
8PFU per 100ml). The
treatment was performed every 3 days for a total of three times for
each mouse and killing the mice after 3 weeks. The tumor volume of
mice treated with Ad.IL-24-Bax were significantly (Po0.05) lower
than those of the other groups. (b) Ad.IL-24-Bax decreased tumor
weight on the tumor-bearing mice. *Po0.05, vs the Ad.Luc group.
#Po0.05 vs the Ad.IL-24 group.
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Cancer Gene Therapywith different apoptosis promoting mechanisms, were
combined to enhance their respective proapoptosis effects
on hepatocellular carcinoma cells. Briefly, the complete
cDNA of IL-24 and the cDNA of Bax a chain were linked
by a hinge zone, EASGGPE, coding for a region of
human IgG1 gene. A 6 His tag was introduced before
the stop codon for the convenience of identification and
purification of the expressed recombinant protein.
VEGF385 with a 10 HRE sequence was designed in
the promoter zone to modulate the expression of IL-24-
Bax, as most solid tumors are anoxic. We found Hep3B
could express adenovirus-mediated recombinant protein
IL-24-Bax with a molecular weight of 47kDa. Under
anoxic conditions, the 10HRE/VEGF385 promoter could
increase the expression of recombinant IL-24-Bax in
hepatocellular carcinoma cells, and the expression level
was increased over time under anoxic conditions.
Studies
25,26 have also shown that the growth inhibition
of tumor cells induced by IL-24 is independent of tumor
suppressor genes and apoptosis-related genes such as
p53, p16, ras, Bax and caspase-3. Bax could induce
permeation of mitochondrial outer membrane, thus
directly causing the release of apoptosis molecules such
as cytochrome C. One of p53’s anti-tumor effects is to
activate mitochondrial-mediated apoptosis by Bax and
other Bcl-2 family members.
10 Three human hepatocel-
lular carcinoma cell lines with differing p53 situations
were selected as test cells in this study: Hep3B is p53-null,
PLC/PRF/5 has mutant p53, and HepG2 has wild-type
p53. The results showed that regardless of p53 status,
Ad.IL-24-Bax could inhibit hepatocellular carcinoma
cell growth and induce apoptosis, and the effects were
increased with the MOI. In addition, when compared with
Ad.IL-24 or Ad.Bax alone, the effects of Ad.IL-24-Bax
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Figure 6 Ad.IL-24-Bax suppressed the proliferation of hepatocellular carcinoma cells and induced apoptosis in hepatocellular carcinoma in vivo.
(a) The treatment was performed every 3 days for a total of three times for each mouse (n¼5) and killed the mice after 3 weeks. Expression of ki-67
in Hep3B tumors was analyzed by immunohistochemistry 3 weeks after the initial injection of transgenic virus, and apoptotic Hep3B cells were
detected by transferase-mediated dUTP nick-end-labeling. (b) The number of positive cells was counted as described in Materials and methods.
*Po0.05, vs the Ad.Luc group.
#Po0.05 vs the Ad.IL-24 group. The results were expressed as means±s.d. of three randomly selected mice.
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Cancer Gene Therapywere more significant and had no obvious cytotoxic
effects on the normal hepatocyte cell line, L02. The
results in the nude mouse hepatoma model were similar:
Ad.IL-24-Bax postponed the growth of the hepatoma
and the effect was more significant than Ad.IL-24 or
Ad.Bax alone. In the hepatoma tissue slice, the expression
of the hepatocellular carcinoma cell proliferation related
antigen ki-67 decreased, and many hepatocellular carci-
noma cells showed signs of apoptosis. It can be inferred
that as the environment of most solid tumors is anoxic,
IL-24-Bax, whose expression was modulated by the HRE
promoter, could enhance the sensitivity and specificity of
the test cells to the anoxic conditions of hepatocellular
carcinoma cells. Moreover, IL-24 or Bax-mediated gene
therapy could inhibit the growth of many kinds of tumor
cells. IL-24 and Bax retained their own independent
effects on tumor cell apoptosis or might act synergisti-
cally, thus Ad.IL-24-Bax’s effect of inhibiting hepatocel-
lular carcinoma cell growth and promoting apoptosis
were more significant than those of Ad.Bax or Ad.IL-24.
On the other hand, normal human hepatocytes were not
obviously affected after infection with Ad.Luc, Ad.Bax,
Ad.IL-24 or Ad.IL-24-Bax. This was due to the selectivity
of IL-24-induced tumor cell apoptosis and the limited
expression of Bax in normal hepatocytes, as the promoter
was regulated by anoxia.
Both IL-24 and Bax can promote apoptosis, only by
different mechanisms. An obvious difference is that IL-24
can activate the ER-stress pathway and induce cell
apoptosis.
18,23,27–31 We addressed this issue by asking
whether the different mechanisms of the recombinant
protein IL-24-Bax can result in an enhanced anti-
hepatoma effect. Did IL-24 and Bax function respectively
or synergistically? Did many apoptosis pathways function
at the same time? To answer these questions, p53-absent
Hep3B cells were selected for further study. To determine
whether the ER-stress pathway was involved or not, we
performed western blots to assess the activation of the ER-
stress pathway related protein Bip/GPR78 and caspase-12,
as well as the expression of the mitochondrial pathway
related protein Bax and activated caspase-3. We inferred
from the results that apoptosis induced by Ad.IL-24-Bax
may involve both the ER-stress pathway and the
mitochondrial pathway. Then, we inhibited the activation
of caspase-12 in the ER-stress pathway with the calpain
inhibitor I (ALLN) to investigate the relationship between
the ER-stress pathway and the mitochondrial pathway.
The results showed that after ALLN treatment, the
activation of caspase-12 in Ad.IL-24-Bax infected Hep3B
cells was significantly inhibited, whereas the expression of
Bax and caspase-3 were not changed, indicating that the
mechanism by which Ad.IL-24-Bax activates the ER-stress
pathway was different from that of Ad.IL-24. Because of
Bax, Ad.IL-24-Bax may induce hepatocellular carcinoma
cell apoptosis by changing the permeabilization of the
mitochondrial membrane or in other unknown ways.
To conclude, the constructed Ad.IL-24-Bax has an
enhanced effect of selectively inducing hepatocellular
carcinoma cell apoptosis, whereas IL-24 and Bax retain
their respective apoptosis-inducing effect. The mechanism
of this enhanced proapoptosis activity involves the dual
effect of the ER-stress pathway and the mitochondrial
pathway. IL-24, a member of the IL-10 family of cytokines,
is produced by monocytes and Th2 cells. Interestingly,
immune cells do not seem to express specific IL-24 receptor
chains; therefore it is unlikely that IL-24 has classical
immune-modulating properties.
32 And the initial interest
in IL-24 did not arise from its physiological signaling
properties through its cognate receptors, but rather from
its tentative ability to selectively kill different cancer cells.
33
Whether the selectivity was related to the specificity of the
receptor or by the bystander effect of secreted IL-24 protein
still remains unknown. We will analyze whether IL-24
can act as targeting molecule to introduce recombinant
molecules to hepatocellular carcinoma cells and enhance
biological activities. It should be noted that we assessed
the anti-tumor activity of chimeric protein IL-24-Bax
using nude mice; but further studies are still needed to
determine its anti-tumor or immunomodulatory activities
in euthymic mice, for the result will determine whether
chimeric protein IL-24-Bax have the potential to develop
into highly specific therapeutic agent against cancer.
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